Canada markets closed

Talis Biomedical Corporation (TLIS)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
9.25+0.05 (+0.54%)
At close: 04:00PM EDT
Currency in USD

Valuation Measures4

Market Cap (intraday) 16.76M
Enterprise Value -34.33M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)48.11
Price/Book (mrq)0.30
Enterprise Value/Revenue -26.65
Enterprise Value/EBITDA 0.86

Trading Information

Stock Price History

Beta (5Y Monthly) 1.66
52-Week Change 328.58%
S&P500 52-Week Change 323.49%
52 Week High 39.60
52 Week Low 34.35
50-Day Moving Average 38.87
200-Day Moving Average 37.50

Share Statistics

Avg Vol (3 month) 37.76k
Avg Vol (10 day) 36.58k
Shares Outstanding 51.82M
Implied Shares Outstanding 61.82M
Float 81.01M
% Held by Insiders 18.31%
% Held by Institutions 143.50%
Shares Short (May 15, 2024) 412.66k
Short Ratio (May 15, 2024) 41.38
Short % of Float (May 15, 2024) 41.09%
Short % of Shares Outstanding (May 15, 2024) 40.69%
Shares Short (prior month Apr 15, 2024) 412.26k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:15
Last Split Date 3Jul 06, 2023

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Mar 31, 2024

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-12,528.77%

Management Effectiveness

Return on Assets (ttm)-31.43%
Return on Equity (ttm)-68.60%

Income Statement

Revenue (ttm)989k
Revenue Per Share (ttm)0.54
Quarterly Revenue Growth (yoy)-94.00%
Gross Profit (ttm)N/A
EBITDA -53.34M
Net Income Avi to Common (ttm)-57.21M
Diluted EPS (ttm)-31.43
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)70.34M
Total Cash Per Share (mrq)38.6
Total Debt (mrq)19.24M
Total Debt/Equity (mrq)33.94%
Current Ratio (mrq)7.51
Book Value Per Share (mrq)31.11

Cash Flow Statement

Operating Cash Flow (ttm)-43.2M
Levered Free Cash Flow (ttm)-29.56M